Medical therapy of active Crohn's disease (1998 study) Skip to main content
Review Baillieres Clin Gastroenterol 1998

Medical therapy of active Crohn's disease

Järnerot G, Sandberg-Gertzén H, Tysk C, Baillieres Clin Gastroenterol, 1998

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The authors reviewed the medical treatments used for active Crohn's disease and pointed toward possible new treatment options.

What They Found

This review of medical treatments for active Crohn's disease found that no definite breakthrough had occurred in recent years, and that results across treatments have varied. The newer salicylates showed some effect at higher doses but did not meet the expectations once connected with their development. The newer steroids compared well to, but did not exceed, older corticosteroids in effectiveness, with a better side-effect profile. Azathioprine and 6-mercaptopurine are slow to take effect and are steroid sparing, while methotrexate has limited controlled data and toxicity concerns. Cyclosporine use is controversial and linked to serious adverse events. Early studies of newer immune-modulating therapies were encouraging, but large-scale studies were still awaited.

What This Means for Canadian Patients

The abstract does not address hyperbaric oxygen therapy (HBOT). It covers only drug treatments for active Crohn's disease, such as salicylates, steroids, immune-suppressing drugs and immune-modulating therapies. Patients with Crohn's disease should talk with their gastroenterologist about these drug options.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This is a narrative review from 1998, so it does not report new patient data, and its own conclusions say large-scale studies of the newer immune therapies were still needed to judge their effects and side effects.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Review
Category Systematic Reviews
Source Pubmed
PubMed ID 9704156
Year Published 1998
Journal Baillieres Clin Gastroenterol
MeSH Terms Adjuvants, Immunologic; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Glucocorticoids; Humans; Hyperbaric Oxygenation; Immunosuppressive Agents; Interferons; Treatment Outcome

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 16, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology